Clinical Trials Logo

Stomatitis clinical trials

View clinical trials related to Stomatitis.

Filter by:

NCT ID: NCT00349024 Active, not recruiting - Pain Clinical Trials

Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer

Start date: July 2005
Phase: N/A
Study type: Interventional

RATIONALE: Polyvinylpyrrolidone-sodium hyaluronate gel may lessen the pain of oral mucositis, or mouth sores, in patients undergoing treatment for cancer. PURPOSE: This clinical trial is studying how well polyvinylpyrrolidone-sodium hyaluronate gel works in reducing pain from oral mucositis in young patients with cancer.

NCT ID: NCT00323518 Completed - Oral Mucositis Clinical Trials

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Start date: May 2006
Phase: Phase 2
Study type: Interventional

CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. The objective of this Phase II trial is to confirm the safety and efficacy of CG53135-05 (velafermin) when administered as a single dose to patients at risk for developing oral mucositis.

NCT ID: NCT00315679 Completed - Clinical trials for Recurrent Aphthous Stomatitis

A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis

Start date: June 1996
Phase: N/A
Study type: Interventional

This is a randomized, double blind, placebo controlled trial of the use of pentoxifylline (oxpentifylline) for the treatment of recurrent mouth ulcers.

NCT ID: NCT00293462 Completed - Clinical trials for Head and Neck Cancer

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Start date: June 7, 2005
Phase: Phase 3
Study type: Interventional

GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy. This randomized clinical trial is studying how well GM-CSF works in preventing and treating mucositis in patients who are undergoing radiation therapy for head and neck cancer.

NCT ID: NCT00289003 Completed - Oral Mucositis Clinical Trials

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy. Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities prevent oral mucositis

NCT ID: NCT00288769 Completed - Clinical trials for Recurrent Aphthous Stomatitis

Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis

Start date: March 2006
Phase: N/A
Study type: Interventional

Background: Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids . Methods: A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets. Purpose of the research: To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS). Study hypothesis: Treatment with vitamin B12 will reduce the recurrence rate and will diminish the symptomatology of RAS episodes.

NCT ID: NCT00267046 Completed - Sarcoma Clinical Trials

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Start date: December 2005
Phase: Phase 2
Study type: Interventional

Primary: 1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients with sarcoma receiving multicycle chemotherapy. 2. To evaluate the pharmacokinetics (PK) of palifermin when given pre chemotherapy. 3. To evaluate the safety profile of palifermin when combined with multicycle chemotherapy. Exploratory: 1. To evaluate the biologic effect of palifermin on oral mucosa. 2. To investigate potential biomarker development by biochemical analysis in blood cells, serum, and plasma. 3. To investigate the effects of genetic variation in mucositis genes, drug metabolism genes, and drug target genes on patient response to the treatment regimen.

NCT ID: NCT00230191 Completed - Clinical trials for Head and Neck Cancer

Safety and Efficacy of RK0202 in Oral Mucositis

Start date: January 2003
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer. Concurrent chemotherapy is not allowed in the study.

NCT ID: NCT00163280 Completed - Mucositis Clinical Trials

Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis

Start date: July 2004
Phase: Phase 2
Study type: Interventional

This purpose of this study is to investigate whether ATL-104 is safe and well tolerated, and whether it shows evidence of efficacy in mucositis in patients undergoing PBSCT

NCT ID: NCT00162526 Withdrawn - Oral Mucositis Clinical Trials

Tocopherol is a Novel Treatment for Cancer Related Mucositis

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The present protocol is an attempt to prevent/treat mucositis in highly susceptible patients subjected to maximally tolerated doses of subsequently-myeloablative or myeloablative doses of chemoradiotherapy supported by autologous or allogeneic stem cell transplantation at the Department of Bone Marrow Transplantation. Mucositis is a major problem in the management of transplant recipients which subjects the patients to the risk of sepsis, need for parenteral nutrition and need of narcotics. We are planning a 2 arm study, comparing 2 safe vitamin E based formulations with placebo.